Global Custom Market Research Reports Provider Company

phone

Blood Cancer Therapeutics: Global Markets to 2023

  • Published Date: 28 Dec 2018
  • Number of Pages: 174
  • Category: Pharmaceuticals
  • Country: Global



The blood cancer therapeutic market was valued at REDACTED in 2017 and is estimated to be REDACTED in 2018. The market is forecasted to reach REDACTED in 2023, growing at a CAGR of REDACTED during the forecast period (2018 to 2023). The global leukemia therapeutic market was valued at REDACTED in 2017 and is forecasted to reach REDACTED in 2023.

The market is witnessing several growth opportunities due to an increase in public and private initiatives to diagnosis the disease, a rise in the number of biopsies conducted annually and the availability of novel drugs. These factors will propel market growth during the forecast years, and the market is projected to grow at a CAGR of REDACTED from2018 to 2023.

The global lymphoma therapeutic market is currently estimated to be worth REDACTED in 2018 and is forecasted to reach REDACTED in 2023. There are several drug approvals for lymphoma involving drug targets as antibody-drug conjugates, programmed death-1 receptor/programmed death ligands and microtubules, among others. The market has several growth opportunities due to premium-priced drug therapies. There are several clinical trials being conducted to bring forth new therapies with novel drug targets.

It was reported that there were 217 active drugs under clinical trials for non-Hodgkin lymphoma in 2018. These factors will propel the growth of the market during the forecast years; it is projected to grow at a CAGR of REDACTED from 2018 to 2023.

The global multiple myeloma therapeutic market is currently estimated to be worth REDACTED in 2018 and is forecasted to reach REDACTED in 2023. The market is undergoing several advances, such as the approval of several drug therapies that have improved overall survival. From 2011 to 2018, nearly seven drugs were approved, including Kyprolis, Imnovid, Pomalyst, Ninlaro, Farydak, Empliciti and Darzalex, which have increased the overall survival of multiple myeloma patients by nearly 23 months. There are several drugs in clinical trials that have the potential to be blockbusters.

The market is highly attractive, and ongoing research will propel the growth of the multiple myeloma market. It is forecasted to grow at a CAGR of REDACTED during the forecast years, 2018 to 2023.
  

Publisher Name : BCC Research


Chapter 1

 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analysts Credentials
BCC Custom Research
Related BCC Research Reports


Chapter 2

Summary and Highlights


Chapter 3

Market Overview
Market Definitions and Overview
Risk Factors
Symptoms
Diagnosis
Treatment and Therapy
Blood Cancer Timeline (Milestones in Research)
Product Approvals
Screening and Prevention Programs
Blood Cancer Awareness Month
The Heroes Among Us Campaign
Spot Leukemia Campaign
Make Blood Cancer Visible Campaign


Chapter 4

 Market Dynamics and Technology Background
Market Drivers
Rising Incidence of Blood Cancer
Highly Sensitive Tests to Detect Minimal Residual Disease
Rising Government and Private Funding for Cancer Treatment
Challenges
Absence of Screening Programs for Early Detection
Low Awareness


Chapter 5

Market Breakdown by Disease Type
Leukemia
Lymphocytic Leukemias
Myelogenous Leukemias
Symptoms
Causes
Diagnosis
Treatment
Stages
Treatment and Therapies
Market Size and Analysis
Acute Lymphoblastic Leukemia (ALL)
Market Size and Analysis
Acute Myeloid Leukemia (AML)
Treatment and Therapies
Market Size and Analysis
Chronic Myeloid Leukemia (CML)
Market Size and Analysis
Chronic Lymphocytic Leukemia (CLL)
First-Line Treatment Regimen
Second-Line Treatment Regimen
Market Size and Analysis
Childhood Leukemia
Non-Hodgkin Lymphoma
Causes and Risk Factors
Signs and Symptoms
Diagnosis
Staging
Treatment
Non-Hodgkin Lymphoma Treatment for Children, Adolescents and Young Adults
Hodgkin Lymphoma
Causes and Risk Factors
Signs and Symptoms
Diagnosis
Staging
Treatment
Hodgkin Lymphoma Treatment for Children and Young Adults
Lymphoma Therapeutics: Market Size and Analysis
Multiple Myeloma
Symptoms
Causes and Risk Factors
Treatment and Therapies
Market Size and Analysis
Hairy Cell Leukemia (HCL)
Immunotherapy


Chapter 6

Blood Cancer Treatment Regimens
Targeted Therapy
B-Cell Leukemia/Lymphoma-2 (BCL-2) Inhibitors
FLT3 Inhibitors
Kinase Inhibitors
IDH Inhibitors
Proteasome Inhibitors
Immunotherapy
Monoclonal Antibodies (mAb) Therapy
Chemotherapy
DNA-Damaging Agents or Alkylating Agents
Antitumor Antibiotics
Antimetabolites
DNA-Repair Enzyme Inhibitors
Topoisomerase Inhibitors
Drug Combination Therapies
Leukemia
Non-Hodgkin Lymphoma
CAR-T Therapy


Chapter 7

Market Breakdown by Region
North American Blood Cancer Therapeutic Market
Epidemiology
Market Size and Analysis
European Blood Cancer Therapeutic Market
Epidemiology
Market Size and Analysis
Asia-Pacific Blood Cancer Therapeutic Market
Epidemiology
Market Size and Analysis
Rest of the World Blood Cancer Therapeutic Market
Epidemiology
Market Size and Analysis


Chapter 8

 Pipeline Analysis
Research and Development Overview
Blood Cancer Drugs Under Development
Promising Pipeline Molecules
Venclexta (AbbVie Inc.)
Empliciti (Bristol-Myers Squibb Co.)
Aplidin (PharmaMar)
SRF231 (Surface Oncology)


Chapter 9

Regulatory and Reimbursement Structure
Overview of Regulations
United States
Canada
Europe
Japan
China
Overview of Pricing and Reimbursement
United States
Europe
Japan


Chapter 10

 Competitive Landscape and Key Developments
Market Structure Analysis
Patent Expiration for Blockbuster Drugs
Key Industry Developments


Chapter 11

 Company Profiles
ABBVIE INC.
Company Overview
Product Information
Development and Strategies
Financials
AMGEN INC.
Product Information
ASTRAZENECA PLC
Company Overview
Product Information
Financials
BOEHRINGER INGELHEIM PHARMACEUTICALS INC.
Company Overview
Financials
Development and Strategies
BRISTOL-MYERS SQUIBB CO.
Company Overview
Product Information
Financials
CELGENE CORP.
Company Overview
Product Information
Financials
GILEAD SCIENCES INC.
Company Overview
Financials
GLAXOSMITHKLINE PLC
Company Overview
Development and Strategies
Financials
F. HOFFMANN-LA ROCHE LTD.
Company Overview
Product Information
Financials
JANSSEN GLOBAL SERVICES LLC
Company Overview
Financials
MERCK & CO., INC.
Company Overview
Product Information
Financials
NOVARTIS AG
Company Overview
Product Information
Financials
PFIZER INC.
Company Overview
Product Information
Financials
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Company Overview
Product Information
Development and Strategies
Financials


Chapter 12

Appendix: Acronyms and Glossary
Acronyms
Glossary of Terms
  



List Of Tables


Summary Table : Global Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 1 : Type of Blood Cancers (Hematological Cancer)
Table 2 : Milestones in the History of Leukemia
Table 3 : Product Approvals, 2016-2018
Table 4 : Classification of Leukemia
Table 5 : Types of Leukemia, Key Features, Occurrence
Table 6 : Diagnostic Examination for Leukemia
Table 7 : PCR Tests
Table 8 : Additional Tests
Table 9 : Treatments for Leukemia
Table 10 : Newer Classes of Drugs
Table 11 : Types of Stem Cell Transplantation
Table 12 : Types of Targeted Therapies
Table 13 : Types of Radiation Therapies
Table 14 : Global Market for Leukemia Therapeutics, by Subtype, Through 2023
Table 15 : Global Market for Leukemia Therapeutics, by Region, Through 2023
Table 16 : Acute Lymphoblastic Leukemia (ALL) Treatment
Table 17 : Therapies Approved for Acute Lymphoblastic Leukemia (ALL)
Table 18 : Global Market for Acute Lymphocytic Leukemia (ALL) Therapeutics, by Region, Through 2023
Table 19 : Therapies Approved for Acute Myeloid Leukemia
Table 20 : Global Market for Acute Myeloid Leukemia Therapeutics, by Region, Through 2023
Table 21 : Therapies Approved for Chronic Myeloid Leukemia
Table 22 : Global Market for Chronic Myeloid Leukemia Therapeutics, by Region, Through 2023
Table 23 : Therapies Approved for Chronic Lymphocytic Leukemia
Table 24 : Global Market for Chronic Lymphocytic Leukemia Therapeutics, by Region, Through 2023
Table 25 : Childhood Leukemia, Five-Year Relative Survival, Age 0-14, 1975-2014
Table 26 : Childhood Leukemia, Five-Year Relative Survival, Age 0-19, 1975-2014
Table 27 : Subtypes of Non-Hodgkin Lymphoma, by Type
Table 28 : Non-Hodgkin Lymphoma, Stages and Modifying Features
Table 29 : Drugs Approved for Non-Hodgkin Lymphoma
Table 30 : Monoclonal Antibodies Approved for Non-Hodgkin Lymphoma
Table 31 : Subtypes of Hodgkin Lymphoma, by Type
Table 32 : Hodgkin Lymphoma, Stages and Modifying Features
Table 33 : Therapies Approved for Classical Hodgkin Lymphoma
Table 34 : Hodgkin Lymphoma, Annual Incidence Rates, 2011-2015
Table 35 : Global Market for Lymphoma Therapeutics, by Region, Through 2023
Table 36 : Effect of Treatment on Multiple Myeloma
Table 37 : Therapies Approved for Multiple Myeloma
Table 38 : Chemotherapy Drugs for Multiple Myeloma
Table 39 : Effect of Treatment on Multiple Myeloma
Table 40 : Global Market for Multiple Myeloma Therapeutics, by Region, Through 2023
Table 41 : Drug Approved for Hairy Cell Leukemia
Table 42 : Global Market for Blood Cancer Therapeutics, by Region, Through 2023
Table 43 : North American Estimated Incidence of Blood Cancer, by Country, 2018
Table 44 : North American Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 45 : North American Market for Leukemia Therapeutics, by Subtype, 2017-2023
Table 46 : North American Market for Blood Cancer Therapeutics, by Country, Through 2023
Table 47 : European Estimated Incidence of Blood Cancer, by Country, 2018
Table 48 : European Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 49 : European Market for Leukemia Therapeutics, by Subtype, 2017-2023
Table 50 : European Market for Blood Cancer Therapeutics, by Country, Through 2023
Table 51 : Asia-Pacific Estimated Incidence of Blood Cancer, by Country, 2018
Table 52 : Asia-Pacific Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 53 : Asia-Pacific Market for Leukemia Therapeutics, by Subtype, Through 2023
Table 54 : Asia-Pacific Market for Blood Cancer Therapeutics, by Country, Through 2023
Table 55 : Rest of the World Estimated Incidence of Blood Cancer, by Country, 2018
Table 56 : Rest of the World Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 57 : Rest of the World Market for Leukemia Therapeutics, by Subtype, Through 2023
Table 58 : Pipeline: Phase I, 2018
Table 59 : Pipeline, Phase II, 2018
Table 60 : Pipeline, Phase III, 2018
Table 61 : Potential Drugs, Indication and Estimated Filing, 2018
Table 62 : Patent Expiration of Blood Cancer Drugs
Table 63 : Key Developments, 2016-2018
Table 64 : AbbVie Inc.: Marketed Products
Table 65 : AbbVie Inc.: Net Revenue, 2015-2017
Table 66 : Amgen Inc.: Marketed Products
Table 67 : AstraZeneca plc: Marketed Products
Table 68 : AstraZeneca plc: Net Revenue, 2014-2017
Table 69 : Boehringer Ingelheim GmbH: Net Revenue, 2015-2017
Table 70 : Bristol-Myers Squibb Co.: Marketed Products
Table 71 : Bristol-Myers Squibb Co.: Net Revenue, 2014-2016
Table 72 : Celgene Corp.: Marketed Products
Table 73 : Celgene Corp.: Net Revenue, 2015-2016
Table 74 : Gilead Sciences Inc.: Net Revenue, 2014-2016
Table 75 : GlaxoSmithKline plc: Net Revenue, 2014-2016
Table 76 : F. Hoffmann-La Roche Ltd.: Marketed Products
Table 77 : F. Hoffmann-La Roche Ltd.: Net Revenue, 2015-2017
Table 78 : Johnson & Johnson Inc.: Net Revenue, 2014-2016
Table 79 : Merck & Co., Inc.: Marketed Products
Table 80 : Merck & Co., Inc.: Net Revenue, 2014-2016
Table 81 : Novartis AG: Marketed Products
Table 82 : Novartis AG: Net Revenue, 2014-2016
Table 83 : Pfizer Inc.: Marketed Products by Indication
Table 84 : Pfizer Inc.: Net Revenue, 2015-2017
Table 85 : Teva Pharmaceutical Industries Ltd.: Marketed Products
Table 86 : Teva Pharmaceutical Industries Ltd.: Net Revenue, 2015-2017
Table 87 : Acronyms Used in This Blood Cancer Therapeutics Report
Table 88 : Glossary of Terms Used in This Blood Cancer Therapeutics Report
  



List Of Figures


Summary Figure : Global Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 1 : Percentage Share of Global Blood Cancer Prevalence, 2018
Figure 2 : Percentage Share of Cancer Incidence in the U.S., by Top 10 Cancer Types, 2018
Figure 3 : U.S. Leukemia Statistics, by Annual Rates (per 100,000 Population) and Number of New Cases (Total Cases), 1999-2016
Figure 4 : Awareness Campaigns
Figure 5 : Types of Leukemia, Key Features, Occurrence
Figure 6 : Global Market for Leukemia Therapeutics, 2017-2023
Figure 7 : Global Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 8 : Global Market Share for Leukemia Therapeutics, by Subtype, 2018
Figure 9 : Global Market Share for Leukemia Therapeutics, by Subtype, 2023
Figure 10 : Global Market for Leukemia Therapeutics, by Region, 2017-2023
Figure 11 : Global Market for Acute Lymphocytic Leukemia (ALL) Therapeutics, 2017-2023
Figure 12 : Global Market for Acute Lymphocytic Leukemia (ALL) Therapeutics, by Region, 2017-2023
Figure 13 : Global Market for Acute Myeloid Leukemia Therapeutics, 2017-2023
Figure 14 : Global Market for Acute Myeloid Leukemia Therapeutics, by Region, 2017-2023
Figure 15 : Global Market for Chronic Myeloid Leukemia Therapeutics, 2017-2023
Figure 16 : Global Market for Chronic Myeloid Leukemia Therapeutics, by Region, 2017-2023
Figure 17 : Global Market for Chronic Lymphocytic Leukemia Therapeutics, 2017-2023
Figure 18 : Global Market for Chronic Lymphocytic Leukemia Therapeutics, by Region, 2017-2023
Figure 19 : Global Market for Lymphoma Therapeutics, 2017-2023
Figure 20 : Global Market for Lymphoma Therapeutics, by Region, 2017-2023
Figure 21 : Global Market for Multiple Myeloma Therapeutics, 2017-2023
Figure 22 : Global Market for Multiple Myeloma Therapeutics, by Region, 2017-2023
Figure 23 : Global Market for Blood Cancer Therapeutics, 2017-2023
Figure 24 : Global Market for Blood Cancer Therapeutics, by Region, 2017-2023
Figure 25 : Percentage Share of North American Leukemia (Estimated) Incidence, by Country, 2018
Figure 26 : Estimated Leukemia Incidence in the United States, by Type, 2016-2018
Figure 27 : Percentage Share of Estimated Blood Cancer Incidence in Canada, 2016
Figure 28 : Percentage Share of North American Non-Hodgkin Lymphoma Estimated Incidence, by Country, 2018
Figure 29 : Percentage Share of North American Hodgkin Lymphoma Estimated Incidence, by Country, 2018
Figure 30 : North American Market for Blood Cancer Therapeutics, 2017-2023
Figure 31 : North American Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 32 : North American Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 33 : North American Market for Blood Cancer Therapeutics, by Country, 2017-2023
Figure 34 : U.K. Top 20 Common Causes of Cancer Death, by Country, 2016
Figure 35 : European Market for Blood Cancer Therapeutics, 2017-2023
Figure 36 : European Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 37 : European Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 38 : European Market for Blood Cancer Therapeutics, by Country, 2017-2023
Figure 39 : Asia-Pacific Market for Blood Cancer Therapeutics, 2017-2023
Figure 40 : Asia-Pacific Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 41 : Asia-Pacific Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 42 : Asia-Pacific Market for Blood Cancer Therapeutics, by Country, 2017-2023
Figure 43 : Rest of the World Market for Blood Cancer Therapeutics, 2017-2023
Figure 44 : Rest of the World Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 45 : Rest of the World Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 46 : Federal and Inter-provincial Approval System for Cancer Drugs in Canada
Figure 47 : AbbVie Inc.: Revenue Share, by Country, 2017
Figure 48 : Boehringer Ingelheim GmbH: Revenue Share, by Region, 2017
Figure 49 : Boehringer Ingelheim GmbH: Revenue Share, by Business Segment, 2017
Figure 50 : Boehringer Ingelheim GmbH: R&D Expenditures, 2015-2017
Figure 51 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, 2017
Figure 52 : Gilead Sciences Inc.: Revenue Share, by Business Segment, 2016
Figure 53 : Gilead Sciences Inc.: Revenue Share, by Country/Region, 2016
Figure 54 : GlaxoSmithKline plc: Revenue Share, by Business Segment, 2016
Figure 55 : GlaxoSmithKline plc: Revenue Share, by Region, 2016
Figure 56 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Segment, 2017
Figure 57 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Region, 2017
Figure 58 : Johnson & Johnson Inc.: Revenue Share, by Business Segment, 2016
Figure 59 : Johnson & Johnson Inc.: Revenue Share, by Country/Region, 2016
Figure 60 : Merck & Co., Inc.: Revenue Share, by Business Segment, 2016
Figure 61 : Merck & Co., Inc.: Revenue Share, by Country/Region, 2016
Figure 62 : Novartis AG: Revenue Share, by Country/Region, 2016
Figure 63 : Novartis AG: Revenue Share, by Business Segment, 2016
Figure 64 : Pfizer Inc.: Revenue Share, by Country/Region, 2016
Figure 65 : Pfizer Inc.: Revenue Share, by Business Segment, 2016
Figure 66 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Region, 2017
Figure 67 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Segment, 2016
  



The global brain tumor therapeutics market was valued at REDACTED in 2017 and is expected to witness a compound annual growth rate (CAGR) of REDACTED, to reach a value of

View Report

The global market size of Hemodialysis Bloodline Systems is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the

View Report

The global market size of Blood Bank Information System is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports